About Contact Us Privacy Policy Corrections
Friday, November 20, 2026

New Blood Cancer Vaccine Cuts Death Risk by 41 Per Cent in Late-Stage Trial

A new vaccine designed to treat one of the most aggressive forms of blood cancer has cut the risk of death by 41 per cent in a major late-stage trial. The treatment, galinpepimut-S, was tested in patients with acute myeloid leukaemia whose cancer had come back after earlier treatment, a group for whom doctors have very few options left. The findings, announced by Sellas Life Sciences on 17 November 2026, raise the prospect of a new maintenance therapy that trains the patient’s own immune system to keep the disease away.

Acute myeloid leukaemia, usually shortened to AML, is a cancer that starts in the bone marrow and spreads quickly into the blood. Around 20,000 people a year are diagnosed with it in the United States alone. Chemotherapy can often push the disease into remission, but for many patients the leukaemia returns, and each return is harder to treat. A bone marrow transplant offers the best chance of a lasting cure for some, yet many patients are too old, too unwell, or unable to find a suitable donor. The new vaccine is designed to work in that gap, between remission and relapse.

Unlike the vaccines given to healthy people to prevent infection, galinpepimut-S is a therapeutic vaccine, given to people who already have cancer. It is built from four small pieces, called peptides, of a protein known as WT1, which leukaemia cells produce in large amounts. The vaccine teaches the immune system to recognise WT1 and attack the leukaemia cells that carry it, including the few that survive chemotherapy and would otherwise seed a relapse. Because it is made in advance rather than tailored to each patient, it is a ready-made treatment, which matters in a disease where time is short.

The vaccine was developed in the laboratory of Dr David Scheinberg at Memorial Sloan Kettering Cancer Center in New York, and is licensed to Sellas. It was tested in the REGAL trial, a global Phase 3 study of 126 patients whose leukaemia had returned after earlier treatment, who had reached a second or later remission, and who could not undergo a stem cell transplant. Half received the vaccine as maintenance treatment, while the other half received the best available treatment chosen by their own doctors. The trial’s main measure was overall survival, the length of time patients lived after joining the study.

The results met the trial’s main goal. Patients who received the vaccine lived for a median of 24 months, compared with 14.7 months for those on the best available treatment, a difference of more than nine months. The risk of death was 41 per cent lower in the vaccine group, a hazard ratio of 0.59 with a statistical strength of p equals 0.035, meaning the result is unlikely to be down to chance. The analysis was carried out after 80 deaths among the 126 patients, the number the trial’s plan had set for its final reading. Sellas also reported that the vaccine was generally well tolerated, with soreness at the injection site the most common side effect, and other side effects mostly mild or moderate.

The announcement still needs the care any early release of trial results deserves. The figures so far are topline results, a summary released by the company, and the detailed findings have not yet been presented at a medical conference or published in a peer-reviewed journal. The release gives no confidence interval for the hazard ratio, the range that would show how precise the 41 per cent figure is, and it does not yet report secondary measures such as how long patients stayed free of leukaemia. The trial was also open-label, meaning patients and doctors knew who was receiving the vaccine. Sellas has said it will present the full results at a future medical meeting and submit them for publication.

Even with those caveats, the result stands out because it was measured in overall survival, the hardest standard a cancer trial can meet, rather than a substitute such as a shrinking tumour. For patients whose leukaemia has already returned once, and who cannot have a transplant, the months after a second remission are among the most uncertain in cancer care, with relapse a constant threat and few treatments to hold it back. A maintenance therapy that works with the immune system rather than adding another round of harsh chemotherapy, and that extends life by more than nine months on average, would change that period from a wait for the disease to return into a period of active treatment.

Sellas now plans to meet the United States Food and Drug Administration about an accelerated route to approval, and is preparing a biologics licence application for the first half of 2027. The vaccine is not approved anywhere yet, and regulators have not reviewed the full trial data, so patients should not expect it immediately. But for a disease that has resisted new approaches for decades, a Phase 3 trial that meets its survival goal is a genuine milestone, and the detailed results, when they arrive, will be watched closely by doctors, patients and researchers around the world.

Maryam Batool

Staff writer at DailyUpdate47, covering breaking news and developing stories.